Medtronic has launched a voluntary exchange offer allowing shareholders to tender MDT shares in return for shares of MiniMed [MMED], the diabetes‑focused business being spun off. The offer provides a slight economic incentive. Tendering shareholders receive more MMED value than MDT value tendered, subject to an upper limit and potential proration if the offer is oversubscribed.
In short, for each $100 in value of MDT accepted for exchange, holders will receive approximately $107.531 of MMED, subject to an upper limit2 of 4.5939 MMED shares per MDT share and potential proration3. Cash will be paid in lieu of fractional shares.
If you reject the offer: You keep your full MDT position with no change in share count, no proration risk, and no exposure to MMED’s post‑spin volatility. Your dividend income remains intact, and MDT continues its march toward becoming a Dividend King.
Taking no action whatsoever amounts to rejecting the offer.
If you accept the offer: You tender some or all of your MDT shares in exchange for MMED, receiving shares based on the final exchange ratio (to be determined on 2026-10-08) and subject to proration. You gain exposure to a newly independent diabetes‑technology company that may offer higher growth potential but potentially greater volatility and no established dividend record.
Instructions for accepting the offer will depend on your brokerage firm and any election to tender must be submitted by 2026-10-08.
For long‑term dividend investors who value MDT’s multi‑decade dividend streak, diversified business model, and proven stability, the most prudent course, the course Royal Dividends will be taking, is to reject the offer and maintain the full MDT position.
- The value of MDT and MMED for purposes of establishing the exchange ratio will be determined by Medtronic by reference to the simple arithmetic average of the daily volume-weighted average prices during the Averaging Period of three consecutive trading days (currently expected to be October 5, 6, and 7) of MDT on the NYSE and MMED on the Nasdaq. The final exchange ratio, including whether the upper limit on the number of shares that can be received for each share of MDT tendered is in effect, will be announced by 9:00 a.m., New York City time, on the trading day immediately preceding the expiration date of the offer. ↩︎
- The upper limit represents a 12% discount for MMED shares based on the closing prices of MDT on the NYSE and MMED on Nasdaq on September 11, 2026. If the upper limit is in effect, you may receive less than $107.53 of MMED for each $100 of MDT tendered, and you could receive much less. ↩︎
- Medtronic may accept only a portion of the shares you tender, meaning most shareholders could be subject to proration. However, investors who beneficially own 99 shares or fewer and tender all of those shares (an “odd‑lot”) will not be subject to proration. Anyone holding 100 shares or more will have their tendered shares prorated if the offer is oversubscribed. ↩︎